Understanding Charcot-Marie-Tooth Disease (CMT): A Critical Unmet Need

Charcot-Marie-Tooth disease (CMT), a hereditary peripheral neuropathy, is characterized by debilitating myelin damage in peripheral nerves. Often manifesting before age 10 with motor dysfunction and sensory abnormalities, CMT is a lifelong condition with no curative treatments currently available. This represents a significant gap in pediatric and chronic disease management, demanding innovative solutions.

​

Addressing the Therapeutic Void in CMT

The complexity of CMT and the stark absence of effective treatments underscore the urgent imperative for groundbreaking therapeutic strategies. At CELLTIUM, we are passionately dedicated to bridging this therapeutic void by pioneering novel treatments directly targeting the root cause of myelin damage in peripheral nerves.

​

Innovative Screening and Biomarker Breakthroughs: Accelerating Drug Discovery

CELLTIUM stands at the forefront with our advanced High-Throughput Screening (HTS) platforms, meticulously engineered to assess critical aspects of nervous system health with unparalleled precision. Our expertly designed platform sustains robust neuro-glial tissue cultures, conquering the long-standing challenge of maintaining long-term cellular interactions - a pivotal innovation for in-depth drug screenings. Complementing this, our sophisticated biomarkers are finely tuned to accurately and rapidly evaluate the efficacy of potential CMT therapies.

​

Advancements in HTS Platform and Drug Discovery: Promising Lead Compounds Identified

Our cutting-edge HTS platform is driving rapid identification of promising lead compounds through a rigorous and efficient screening process. These compounds have demonstrated compelling therapeutic effects in our preclinical models. Our ongoing research is intensely focused on deciphering their precise molecular targets, mechanisms of action, pharmacokinetics, and ADMET profiles, paving the way for effective drug development.

​

Setting New Standards in CMT Research and Treatment: Targeting the Root Pathology

CELLTIUM’s innovative approach uniquely targets the primary pathology of CMT – myelin damage in peripheral nerves. This distinct focus allows us to develop treatments that transcend symptom management, setting our research apart from conventional approaches. Our data indicates superior efficacy, redefining the therapeutic potential for CMT and positioning CELLTIUM as a pioneering force in the field.

​

Focused Target-Based Drug Development: Strategic and Efficient

In our relentless quest for groundbreaking CMT therapeutics, CELLTIUM employs a highly focused, target-based drug development strategy. We are rigorously exploring a range of critical molecular interactions and pathways that hold immense promise for effective CMT treatment. This strategic approach not only fortifies our competitive advantage but also accelerates the advancement of our transformative research.

​

Leading the Charge Against CMT: Transforming Lives Through Innovation

CELLTIUM is resolutely committed to developing treatments that go beyond mere symptom relief, tackling the underlying causes of CMT at its core. Our unwavering goal is to transform the lives of individuals affected by this debilitating condition through cutting-edge research, while upholding the highest standards of confidentiality and scientific rigor.

​

Stay Updated on Our Progress:Follow CELLTIUM's journey towards a brighter future in Biotechnology and Translational Sciences for the latest research breakthroughs and advancements in CMT treatment.